Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIT | P10721 | 3/20 | 0.57 |
| ▸ | PDGFRB | P09619 | 8/20 | 0.52 |
| ▸ | PDGFRA | P16234 | 4/20 | 0.52 |
| ▸ | FLT3 | P36888 | 1/20 | 0.52 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 2/20 | 0.49 |
| ▸ | BACE1 | P56817 | 4/20 | 0.47 |
| ▸ | ACHE | P22303 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | GBA1 | P04062 | 2/20 | 0.46 |
| ▸ | AKT1 | P31749 | 1/20 | 0.45 |
| ▸ | AKT2 | P31751 | 1/20 | 0.45 |
| ▸ | AKT3 | Q9Y243 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2798395 | 0.91 | HTT (0.61) | KITPDGFRBPDGFRAFLT3MAP4K4 | |
| SCHEMBL30902259 | 0.91 | HTT (0.61) | KITPDGFRBPDGFRAFLT3MAP4K4 | |
| SCHEMBL3768455 | 0.85 | PRKDC (0.57) | KITPDGFRBPDGFRAMAP4K4BACE1 | |
| SCHEMBL12215173 | 0.84 | KIT (0.64) | KITPDGFRBMAP4K4HTTGBA1 | |
| SCHEMBL30902145 | 0.83 | KIT (0.53) | KITPDGFRBPDGFRAFLT3MAP4K4 | |
| SCHEMBL31029781 | 0.83 | KIT (0.53) | KITPDGFRBPDGFRAFLT3MAP4K4 | |
| SCHEMBL30902163 | 0.83 | KIT (0.52) | KITPDGFRBPDGFRAFLT3MAP4K4 | |
| SCHEMBL16637964 | 0.83 | KIT (0.52) | KITPDGFRBPDGFRAFLT3MAP4K4 | |
| SCHEMBL22028940 | 0.83 | KIT (0.52) | KITPDGFRBPDGFRAFLT3MAP4K4 | |
| SCHEMBL29611800 | 0.83 | KIT (0.52) | KITPDGFRBPDGFRAFLT3MAP4K4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250145589-A1 | PYRIDINE DERIVATIVE AND USE THEREOF | SICHUAN HUIYU PHARMACEUTICAL CO., LTD. (CN) | 2025-05-08 | — | — | US | disclosed |
| EP-4406948-A1 | PYRIDINE DERIVATIVE AND USE THEREOF | Sichuan Huiyu Pharmaceutical Co., Ltd. (CN) | 2024-07-31 | — | — | EP | disclosed |
| CN-117957219-A | Pyridine derivative and application thereof | 四川汇宇制药股份有限公司 | 2024-04-30 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250145589-A1 | PYRIDINE DERIVATIVE AND USE THEREOF | KRAS, NRAS, BRAF | KIT 1162/4885PDGFRB 693/4885PDGFRA 1044/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.